)
Bengaluru-based biopharmaceuticals major Biocon Ltd, has received approval for its Insulin Glargine by Cofepris, the Mexican health authority, through its partner PiSA Farmaceutica.
Mexico has been a very important market for Biocon from 2006 where it has been playing a significant role in enabling access to affordable rh-Insulin.
Insulin Glargine will augment the affordable insulins therapy for diabetes management. Galactus by PiSA is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012.
Biocon currently has marketing approvals in over 60 countries for its rh-Insulin and in over 20 countries for Insulin Glargine.
Biocon Chairperson & Managing Director Kiran Mazumdar-Shaw said: ?We are committed to make a global impact with our affordable insulins therapy. Our Insulin Glargine will now enable access to a basal insulin which will further expand the diabetes management therapy for patients in Mexico."
